Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of nintedanib in preparing medicament for preventing and treating liver fibrosis and hepatocirrhosis

A technology of nintedanib and medicine, which is applied in the field of application of nintedanib in the preparation of drugs for the prevention and treatment of liver fibrosis and liver cirrhosis, can solve the problems that have not been revealed that nintedanib has anti-hepatic cirrhosis and anti-hepatic fibrosis. the role of

Inactive Publication Date: 2017-05-24
THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] There is no disclosure in the prior art that nintedanib has anti-cirrhosis and anti-fibrosis effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of nintedanib in preparing medicament for preventing and treating liver fibrosis and hepatocirrhosis
  • Application of nintedanib in preparing medicament for preventing and treating liver fibrosis and hepatocirrhosis
  • Application of nintedanib in preparing medicament for preventing and treating liver fibrosis and hepatocirrhosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 Effect of nintedanib on Src kinase activity in human hepatic stellate cells LX-2

[0042] 1. Experimental materials

[0043] LX-2 cells were provided by Capital Medical University; Nintedanib was provided by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.; Phospho-Src Family (Tyr416) ​​primary antibody was purchased from Cell Signaling Technology Company, Cat. No. #6943; GAPDH- Antibody was purchased from Beijing Zhongshan Jinqiao Biotechnology Co., Ltd., the article number was TA-08; TGF-β was purchased from R&D Systems Company, the article number was 240-B-002.

[0044] 2. Experimental method

[0045] The LX-2 cells were divided into 5×10 5 Each well was inoculated in a 6-well plate, cultured overnight, and then replaced with serum-free DMEM medium, starved for 24 hours (h), and replaced with serum-free dilution concentrations of 0 μm, 0.1 μm, 0.5 μm, 1 μm, respectively. Treat the cells with 5 μm nintedanib for 4 hours, and then stimulate the cells wit...

Embodiment 2

[0048] Example 2 Effect of nintedanib on the production of α-SMA by human hepatic stellate cells LX-2

[0049] 1. Experimental materials

[0050] Anti-α-SMA primary antibody was purchased from Abcam Company, the product number is ab5694.

[0051] 2. Experimental method

[0052] The LX-2 cells were divided into 5×10 5 Each well was inoculated in a 6-well plate, cultured overnight, and then replaced with serum-free DMEM medium. After 24 hours of starvation culture, replaced with 2% serum, 10ng / mL TGF-β and concentrations of 0μm, 0.1μm, 0.5 The treated cells were incubated with DMEM medium of μm, 1 μm, and 5 μm nintedanib, washed twice with PBS at room temperature after 12 hours, and 120 μL of protein lysate was added to collect the cells to obtain samples. The samples were subjected to western blot to detect the level of α-SMA.

[0053] 3. Experimental results

[0054] like figure 2 As shown, nintedanib can inhibit TGF-β-induced α-SMA production in human hepatic stellate ...

Embodiment 3

[0055] Example 3 Effect of nintedanib on proliferation activity of human hepatic stellate cell LX-2 and rat hepatic stellate cell HSC-T6

[0056] 1. Experimental materials

[0057] Cell Counting Kit 8 (Cell Counting Kit-8, CCK-8) was purchased from Dongren Chemical Technology Co., Ltd., the article number is CK04.

[0058] 2. Experimental method

[0059] Inoculate LX-2 cells and HSC-T6 cells in 96-well plates at 3000 cells / well, culture overnight, and then replace with serum-free DMEM medium. After 24 hours of starvation culture, replace with 2% serum, 10ng / mL TGF -β and concentrations of 0 μm, 0.1 μm, 0.5 μm, 1 μm, and 5 μm nintedanib were used to incubate the treated cells in DMEM medium, and the “control” group was cultured in DMEM medium with 2% serum (without adding TGF-β nor ganidanib treatment). At 0h, 24h, 48h and 72h after adding the drug, measure the cell viability and density with CCK-8: suck out the medium, add 100 μL of CCK-8 solution diluted 10 times with the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of nintedanib in preparing medicament for preventing and treating liver fibrosis and hepatocirrhosis. The invention proves that nintedanib is capable of obviously reducing the degree of liver fibrosis or hepatocirrhosis and alleviating hepatic injury, is free from obvious hepatotoxicity and has favorable application prospect.

Description

technical field [0001] The invention relates to a new medical application of nintedanib, in particular to the application of nintedanib in the preparation of medicines for preventing and treating liver fibrosis and liver cirrhosis. Background technique [0002] Liver cirrhosis is one of the common chronic diseases that seriously endanger human health. Liver fibrosis is the pathological basis of liver cirrhosis. Various etiologies (such as viral hepatitis, alcoholic liver disease, non-alcoholic liver disease, drug and chemical factor damage, etc.) can cause liver damage and inflammation, leading to liver fibrosis and eventually developing For cirrhosis of the liver. Hepatic fibrosis is a pathological process in which excessive deposition of collagen-based extracellular matrix occurs in the liver under the stimulation of various chronic injuries, followed by changes in the structure of liver lobules and liver function. At present, it is believed that liver fibrosis is a reve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/496A61P1/16
Inventor 陆荫英王晶杜桂芳徐宏江冯德春丁强曾珍荣光华陈艳杨新瑞卢姗姗张翠红宋伟申恒巧
Owner THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com